Stockscreener 앱 받기
3.98
1.40%
0.06
전일 마감가:
$3.92
열려 있는:
$3.98
하루 거래량:
135.12K
Relative Volume:
0.05
시가총액:
$369.76M
수익:
-
순이익/손실:
$-48.17M
주가수익비율:
-6.9825
EPS:
-0.57
순현금흐름:
$-37.10M
1주 성능:
-3.05%
1개월 성능:
-14.33%
6개월 성능:
-62.36%
1년 성능:
-53.07%
1일 변동 폭
$3.94
$4.06
1주일 범위
$3.745
$4.54
52주 변동 폭
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
3.99 | 363.27M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.46 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.88 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
839.43 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.20 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.58 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Singapore
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript - Insider Monkey
Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) - Yahoo Finance
D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences reports fiscal 2026 first quarter financial results and provides business update - marketscreener.com
Anavex Life Sciences Q1 Earnings Call Highlights - Yahoo Finance
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot - marketscreener.com
Anavex Life Sciences : Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update - marketscreener.com
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
Chipmakers Recap: Does Unity Bancorp Inc meet Warren Buffetts criteriaJuly 2025 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Anavex Life Sciences (AVXL) Price Target Decreased by 25.00% to 33.66 - MSN
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock - Investing.com
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock By Investing.com - Investing.com Nigeria
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - MarketBeat
Trading Action: Can Anavex Life Sciences Corp weather a recessionDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Returns Recap: Why Anavex Life Sciences Corp. stock could rally in 2025Market Risk Report & Momentum Based Trading Ideas - Bộ Nội Vụ
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Anavex Life Sciences
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Eastern Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - Eastern Progress
Why Anavex Life Sciences Corp. stock could rally in 2025Portfolio Update Report & Free Community Consensus Stock Picks - Улправда
Will Anavex Life Sciences Corp. stock continue upward momentumPortfolio Gains Summary & Technical Pattern Recognition Alerts - Улправда
Franklin Credit Management CorporationAVXL ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - FinancialContent
When Will Anavex Life Sciences Corp. (NASDAQ:AVXL) Turn A Profit? - 富途牛牛
Is Anavex Life Sciences Corp. stock a buy for dividend growth2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Anavex Life Sciences Appoints Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology - citybiz
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Anavex Life Sciences
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Shares Surge on Encouraging Regulatory Development - AD HOC NEWS
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Anavex Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL - Chartmill
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.44%
자본화:
|
볼륨(24시간):